Results 61 to 70 of about 14,752 (202)

Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

Cells, 2022
Pemphigus vulgaris is an autoimmune blistering disease of the epidermis, caused by autoantibodies against desmosomal proteins, mainly desmogleins 1 and 3, which induce an impairment of desmosomal adhesion and blister formation. Recent findings have shown
Anna Zakrzewicz, Celina Würth, Benedikt Beckert, Simon Feldhoff, Katrien Vanderheyden, Stian Foss, Jan Terje Andersen, Hans de Haard, Peter Verheesen, Vladimir Bobkov, Ritva Tikkanen   +10 more
doaj   +1 more source

Cellular expression and crystal structure of the murine cytomegalovirus MHC-Iv glycoprotein, m153 [PDF]

, 2007
Mouse cytomegalovirus (MCMV), a β-herpesvirus that establishes latent and persistent infections in mice, is a valuable model for studying complex virus-host interactions.
Balbo, Andrea, Eikel, Daniel, Hess, Sonja, Jonjić, Stipan, Mans, Janet, Margulies, David H., Natarajan, Kannan, Robinson, Howard, Schuck, Peter, Tiemessen, Caroline T., Šimić, Hrvoje   +10 more
core   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

Podocyte-specific knockout of the neonatal Fc receptor (FcRn) results in differential protection depending on the model of glomerulonephritis.

PLoS ONE, 2020
Podocytes have been proposed to be antigen presenting cells (APCs). In traditional APCs, the neonatal Fc receptor (FcRn) is required for antigen presentation and global knockout of FcRn protects against glomerulonephritis.
James F Dylewski, Pantipa Tonsawan, Gabriela Garcia, Linda Lewis, Judith Blaine   +4 more
doaj   +1 more source

Single Shot Text Detector with Regional Attention

, 2017
We present a novel single-shot text detector that directly outputs word-level bounding boxes in a natural image. We propose an attention mechanism which roughly identifies text regions via an automatically learned attentional map.
He, Pan, He, Tong, Huang, Weilin, Li, Xiaolin, Qiao, Yu, Zhu, Qile   +5 more
core   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab

Frontiers in Pharmacology, 2021
Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-
Lei Wang, Lei Wang, Lixiong Liu, Xiaoping Hong, Dongzhou Liu, Zeneng Cheng   +5 more
doaj   +1 more source

Nipocalimab‐aahu in generalised myasthenia gravis: A new Fc receptor‐targeted option for antibody‐positive patients

Ibrain, EarlyView.
Generalised myasthenia gravis (gMG) can be effectively treated with nipocalimab (Imaavy), a new FcRn inhibitor that selectively lowers harmful IgG levels without causing widespread immunosuppression. According to Phase 2/3 trials, nipocalimab exhibits favourable safety, broad age applicability (≥12 years), and sustained efficacy, setting it apart as a ...
Jawairya Muhammad Hussain, Anoosha Ashfaq, Azka Shahid, Fatima Mudassir   +3 more
wiley   +1 more source

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS [PDF]

, 2016
Treatment of Guillain-Barré syndrome with a standard course of high-dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG
Doorn, P.A. (Pieter) van, Fokkink, W.-J.R. (Willem-Jan), Haarman, A.E.G. (Annechien E. G.), Huizinga, R. (Ruth), Jacobs, B.C. (Bart), Rijs, W. (Wouter) van, Tio-Gillen, A.P. (Anne)   +6 more
core   +1 more source

Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease

The Journal of Clinical Pharmacology, EarlyView.
Abstract Many patients with inflammatory bowel disease (IBD) do not adequately respond to infliximab, potentially due to individual differences in pharmacokinetics (PK). This study aimed to identify clinical and biochemical variables associated with infliximab PK.
Ilse A. Pool, Ilse Volkerink, Mirthe Stavast, Jos G. W. Kosterink, Gerard Dijkstra, Paola Mian, Arno R. Bourgonje   +6 more
wiley   +1 more source